However, in patients with locally advanced breast cancer, ZOL combined with neoadjuvant chemotherapy had no significant effect on clinical outcomes in the overall cohort and, surprisingly, was also associated with increased extraosseous recurrence and shorter survival in patients with ER+/HER2- cancer who were less than 45 years of age [165]. Here, ESR1 is linked to breast cancer.